ArticlePakistan journal of medical sciences2026
Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the efficacy of lenvatinib combined with sintilimab versus transcatheter arterial chemoembolization (TACE) in the conversion therapy for unresectable hepatocellular carcinoma (HCC). Methodology: A retrospective analysis of the clinical data of 153 patients with unresectable HCC admitted to the Affiliated Hospital of Nanhua University from January 2023 to December 2024 was performed. According to the treatment regimens, the patients were divided into two groups: the study group (n=79) treated with lenvatinib plus sintilimab and the control group (n=74) treated with TACE. The efficacy of conversion therapy, tumor marker levels, tumor morphological features, blood supply, and adverse reactions were compared between the two groups. Results: Compared with those in the control group, the objective response rate (ORR) (67.09% vs. 47.30%, p=0.013), disease control rate (DCR) (91.14% vs. 79.73%, p=0.044), and conversion resection rate (48.10% vs. 28.38%, p=0.012) in the study group were significantly greater. Similarly, compared with the control group, the study group also exhibited lower levels of alpha-fetoprotein (AFP) (245.76±108.54 ng/mL vs. 186.42±95.37 ng/mL, p<0.0001), protein induced by vitamin K absence or antagonist II (PIVKA-II) (309.25±96.78 ng/mL vs. 245.68±82.35 ng/mL, p<0.0001), and chemokine (C-C motif) ligand 2 (CCL2) (71.76±23.81 ng/mL vs. 58.36±18.42 ng/mL, p<0.0001). Additionally, the blood flow signal intensity of tumor-feeding arteries (t=5.620; p<0.001), reduction rate of maximum tumor diameter (t=3.436; p<0.001), and tumor necrosis rate (t=7.025; p<0.001) were significantly better in the study group than in the control group. There was no significant difference in the incidence of adverse reactions, including hand-foot skin reactions (p=0.474), gastrointestinal reactions (p=0.875), liver function injury (p=0.672), myelosuppression (p=0.539), or fever (p=0.392), between the two groups (P>0.05). Conclusion: Compared with TACE, lenvatinib combined with sintilimab can improve the therapeutic efficacy of conversion therapy for unresectable HCC, with comparable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.